<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

5637

Description

5637 (Bladder Cancer CDX Model)

The 5637 bladder cancer cell line was derived from a grade II urinary bladder carcinoma. Classified as a transitional cell carcinoma, it is widely used in studies of urothelial cancer. The model offers consistent growth and reproducibility, making it a reliable system for oncology research. Researchers use 5637 to explore new therapeutic approaches in bladder cancer. 

Key Features: 

  • Derived from a human urinary bladder carcinoma (grade II). 
  • Representative of transitional cell carcinoma.
  • Moderate tumorigenicity in xenografts. 
  • Useful for bladder cancer drug discovery and testing. 

Applications: 
5637 is applied in studies of urothelial carcinoma drug response and biomarker development. The model supports preclinical screening of chemotherapies and targeted therapies. Its consistency makes it valuable for reproducibility in research programs. Investigators often use 5637 to assess mechanisms of bladder cancer progression.

Details
Tumor Type
Bladder
Tumor Subtype
Grade II Carcinoma
Organism
Human
Mouse Sex
Female
Mouse Strain
NOG
Mutated Genes
ATM
Mutation: p.H1876Q
Effect: Missense Variant
Impact: Uncertain Significance
ERBB2
Mutation: p.S310F
Effect: Missense Variant
Impact: Likely Pathogenic
TERT
Effect: Upstream Gene Variant
Impact: Pathogenic & Likely Pathogenic & Uncertain Significance
*Data provided by DepMap
TP53
Mutation: p.R280T
Effect: Missense Variant
Impact: Likely Pathogenic & Pathogenic
Lumin Data
Proteomics RNASeq WES
Expression Data
Growth Curve
View on Lumin